Joel Greenblatt’s EW Holdings & Trades

First Buy
Q2 2013
Duration Held
50 Quarters
Largest Add
Q2 2014
+1.12 M Shares
Current Position
33,456 Shares
$2.6 M Value

Joel Greenblatt's EW Position Overview

Joel Greenblatt (via Gotham Asset Management, LLC) currently holds 33,456 shares of Edwards Lifesciences Corporation (EW) worth $2.6 M, representing 0.01% of the portfolio. First purchased in 2013-Q2, this long-term strategic position has been held for 50 quarters.

Based on 13F filings since 2013, Joel Greenblatt has maintained a long-term strategic position in EW, representing a significant commitment to this investment thesis. Largest addition occurred in Q2 2014, adding 1.12 M shares. Largest reduction occurred in Q2 2015, reducing 783,318 shares.

Analysis based on 13F filings available since 2013 Q2

Joel Greenblatt's Edwards Lifesciences Corporation (EW) Holding Value Over Time

Track share changes against reported price movement

Quarterly Edwards Lifesciences Corporation (EW) Trades by Joel Greenblatt

Period Bought/Sold (Sh.) % Change Qtr. End Shares Reported Price
Q2 2013 +252,738 Add 0.00% 252,732 $11.20
Q3 2013 -66,186 Reduce 26.19% 186,546 $11.61
Q4 2013 +520,014 Add 278.76% 706,560 $10.96
Q1 2014 -276,426 Reduce 39.12% 430,134 $12.36
Q2 2014 +1.12 M Add 261.38% 1.55 M $14.31
Q3 2014 +83,526 Add 5.37% 1.64 M $17.02
Q4 2014 -150,708 Reduce 9.20% 1.49 M $21.23
Q1 2015 -38,454 Reduce 2.59% 1.45 M $23.74
Q2 2015 -783,318 Reduce 54.07% 665,484 $23.74
Q3 2015 -618,822 Reduce 92.99% 46,662 $23.70
Q4 2015 -46,662 Sold Out 46,662 $0.00
Q2 2016 +17,511 New Buy 17,511 $33.24
Q3 2016 -17,511 Sold Out 17,511 $0.00
Q3 2017 +23,808 New Buy 23,808 $36.42
Q4 2017 +88,815 Add 373.05% 112,623 $37.57
Q1 2018 -112,623 Sold Out 112,623 $0.00
Q4 2019 +89,811 New Buy 89,811 $77.76
Q1 2020 -89,811 Sold Out 89,811 $0.00
Q2 2020 +16,482 New Buy 16,482 $69.11
Q3 2020 -16,482 Sold Out 16,482 $0.00
Q3 2021 +10,246 New Buy 10,246 $113.21
Q4 2021 -4,593 Reduce 44.83% 5,653 $129.49
Q1 2022 +13,398 Add 237.01% 19,051 $117.74
Q2 2022 -12,995 Reduce 68.21% 6,056 $95.11
Q3 2022 +20,684 Add 341.55% 26,740 $82.65
Q4 2022 +24,513 Add 91.67% 51,253 $74.61
Q1 2023 -4,731 Reduce 9.23% 46,522 $82.73
Q2 2023 -24,129 Reduce 51.87% 22,393 $94.33
Q3 2023 -10,835 Reduce 48.39% 11,558 $69.28
Q4 2023 +6,738 Add 58.30% 18,296 $76.25
Q1 2024 -6,468 Reduce 35.35% 11,828 $95.56
Q2 2024 +30 Add 0.25% 11,858 $92.37
Q3 2024 -3,879 Reduce 32.71% 7,979 $65.99
Q4 2024 +8,444 Add 105.83% 16,423 $74.03
Q1 2025 +27,237 Add 165.85% 43,660 $72.48
Q2 2025 -365 Reduce 0.84% 43,295 $78.21
Q3 2025 -9,839 Reduce 22.73% 33,456 $77.77

Joel Greenblatt's Edwards Lifesciences Corporation Investment FAQs

Joel Greenblatt first purchased Edwards Lifesciences Corporation (EW) in Q2 2013, acquiring 252,732 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

Joel Greenblatt has held Edwards Lifesciences Corporation (EW) for 50 quarters since Q2 2013. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

Joel Greenblatt's largest addition to Edwards Lifesciences Corporation (EW) was in Q2 2014, adding 1,554,438 shares worth $22.24 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

According to the latest 13F filing for Q3 2025, Joel Greenblatt's firm, Gotham Asset Management, LLC, owns 33,456 shares of Edwards Lifesciences Corporation (EW), valued at approximately $2.6 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

As of the Q3 2025 filing, Edwards Lifesciences Corporation (EW) represents approximately 0.01% of Joel Greenblatt's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

Joel Greenblatt's peak holding in Edwards Lifesciences Corporation (EW) was 1,637,964 shares, as reported at the end of Q3 2014. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.